prurigo nodularis
Conditions
Interventions
Atopic Prurigo Nodularis (APN) group:none
Non-Atopic Prurigo Nodularis (NAPN) group:none
Sponsors
Huashan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: PN 1. Presentation of a history of chronic severe itching, with clinical findings typically showing symmetrical distribution of characteristic PN verrucous nodular lesions. 2. Individuals aged between 18 and 75 years, inclusive, of both genders are eligible. 3. Patients with atopic PN must meet the diagnostic criteria for atopic dermatitis (AD) or have a previous diagnosis of AD, whereas patients with non-atopic PN do not. 4. The duration of the disease should be at least 6 months. 5. Skin pathology and direct immunofluorescence examination of the skin can be used to support the diagnosis of PN. 6. Understanding and signing of the informed consent form is required. healthy control 7. Individuals aged between 18 and 75 years, inclusive, of both genders are eligible. 8. The gender and age are matched with the PN group.
Exclusion criteria
Exclusion criteria: PN 1. Presence of skin diseases other than PN that could potentially interfere with the study outcome. 2. Antihistamine medication taken within the past week. 3. Administration of compound glycyrrhizin preparations within the last two weeks. 4. Systemic use of glucocorticoids, immunosuppressants, GABA drugs, antidepressants, small molecule drugs (such as JAK, Janus kinase inhibitors), etc., within the past month. 5. Topical application of glucocorticoids, calcineurin inhibitors, or vitamin D derivatives within the past three days. 6. Active or severe systemic diseases: uncontrolled diabetes, cardiovascular diseases, liver or kidney dysfunction, active tuberculosis, autoimmune diseases, neurological diseases, etc. 7. Female patients who are pregnant or breastfeeding. healthy control 8. History of allergic diseases. 9. Have taken antihistamine drugs within the past week. 10. Have taken compound glycyrrhizin drugs within the past two weeks. 11. Within the past month, systematic use of glucocorticoids, immunosuppressants, GABA drugs, antidepressants, biological targeted preparations, small molecule drugs (such as JAK inhibitors), etc. has been carried out. 12. Glucocorticoids, calcineurin inhibitors or vitamin D derivatives have been applied externally within the past 3 days. 13. Active or severe systemic diseases: uncontrolled diabetes, cardiovascular diseases, liver and kidney insufficiency, active pulmonary tuberculosis, autoimmune diseases, neurological diseases, etc. 14. Female patients who are pregnant or breastfeeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the Investigator Global Assessment (IGA) scores;total IgE in the serum;the Peak Pruritus-Numerical Rating Scale (PP-NRS) scores;Neural fiber immunofluorescence staining;DSP spatial transcriptome sequencing;RNA hybridization in situ;eosinophils count; | — |
Secondary
| Measure | Time frame |
|---|---|
| the Sleep Disturbance-Numerical Rating Scale (SD-NRS) scores;the Hospital Anxiety and Depression Scale (HADS) scores;the Dermatology Life Quality Index (DLQI) scores; | — |
Countries
China
Contacts
Public ContactHui Tang
Huashan Hospital, Fudan University
Outcome results
None listed